<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02646930</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00067725</org_study_id>
    <nct_id>NCT02646930</nct_id>
  </id_info>
  <brief_title>Chronic Endometritis and IVF</brief_title>
  <acronym>CEIVF</acronym>
  <official_title>The Impact of Chronic Endometritis on IVF Pregnancy and Pregnancy Loss Rates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Embryo quality is known to be a very important determinant to predict the&#xD;
      implantation and pregnancy rate in IVF patients, however, the role of uterine integrity or&#xD;
      endometrial receptivity cannot be overlooked.&#xD;
&#xD;
      Chronic endometritis (CE) is an inflammation of the endometrium diagnosed by the presence of&#xD;
      plasma cells in the endometrial stroma. There is not only no census on the definition of CE,&#xD;
      the current literature on the impact of CE on reproductive outcome is controversial and&#xD;
      consists only of retrospective studies with small sample sizes. Although there is a&#xD;
      presumption that CE is related to poor IVF outcome, this belief has not been proven.&#xD;
&#xD;
      Design: Prospective cohort study&#xD;
&#xD;
      Setting: Infertility clinics of 2 academic medical centers&#xD;
&#xD;
      Patients: Patients between the ages of ≥ 21 and ≤ 35 years old undergoing their first IVF&#xD;
      cycle will be invited to participate.&#xD;
&#xD;
      Main Outcome Measures: The primary outcome will be ongoing pregnancy after 12 weeks estimated&#xD;
      gestational age (EGA) with previously documented fetal cardiac motion. Secondary outcomes&#xD;
      will include pregnancy loss rate as defined by chemical pregnancy, blighted ovum or loss of&#xD;
      fetal cardiac motion before 12 weeks EGA.&#xD;
&#xD;
      Materials and Methods: The cycle prior to IVF, patients will undergo an in-office endometrial&#xD;
      biopsy on cycle days 19-24. Samples will be stained for CD138 and the number of plasma cells&#xD;
      will be quantified. The number of plasma cells in a sample that yields the best sensitivity&#xD;
      and specificity for pregnancy will be determined by a Receiver-Operator-Curve. This number&#xD;
      will then be used as a dichotomous variable to assign categories of &quot;positive for CE&quot; and&#xD;
      &quot;negative for CE.&quot; Pregnancy and miscarriage rates will then be determined in the positive&#xD;
      and negative CE sample with Chi Square Analysis. A secondary sub analysis will be performed&#xD;
      to determine pregnancy and miscarriage rates in patients who declined to participate in the&#xD;
      study.&#xD;
&#xD;
      Expected Results: The investigators hypothesize that higher rates of CE will be found in&#xD;
      women failing to conceive with IVF and with subsequent first-trimester miscarriage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2016</start_date>
  <completion_date type="Actual">May 16, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy loss rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Chronic Endometritis</condition>
  <condition>in Vitro Fertilization</condition>
  <arm_group>
    <arm_group_label>Incidence of CE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine rates of CE in women undergoing initial IVF and outcomes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endometrial biopsy</intervention_name>
    <description>Endometrial biopsy in women undergoing first IVF cycle</description>
    <arm_group_label>Incidence of CE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of ≥ 21 and ≤ 35 years old&#xD;
&#xD;
          -  undergoing first IVF cycle&#xD;
&#xD;
          -  a diagnosis of ovulatory dysfunction, pelvic factor, male factor, cervical factor or&#xD;
             unexplained infertility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 40 kg/m2, anti-mullerian hormone (AMH) &lt; 1.0 ng/mL or antral follicle count &lt;10&#xD;
&#xD;
          -  previous endometrial ablation&#xD;
&#xD;
          -  previous uterine artery embolization&#xD;
&#xD;
          -  presence of type 0, 1, 2, 3 fibroid tumor&#xD;
&#xD;
          -  presence of type 4 fibroid tumor with a mean diameter of &gt; 4 cm&#xD;
&#xD;
          -  presence of uterine anomaly other than arcuate configuration&#xD;
&#xD;
          -  presence of an endometrial polyp or endometrial synechiae&#xD;
&#xD;
          -  presence of a hydrosalpinx on hysterosalpingography or ultrasound&#xD;
&#xD;
          -  positive gonorrhea and chlamydia DNA testing&#xD;
&#xD;
          -  Patients on chronic glucocorticoids (except nasal preparations), or using&#xD;
             glucocorticoids for assisted hatching will be excluded.&#xD;
&#xD;
          -  Patients on monoclonal antibody preparations directed to TNFα will be excluded.&#xD;
&#xD;
          -  Post-enrollment exclusion will include patients receiving any antibiotics, except&#xD;
             prophylaxis for transvaginal oocyte retrieval (TVOR) or glucocorticoids, except nasal&#xD;
             preparations, from the time of endometrial biopsy until initial transvaginal&#xD;
             ultrasound (TVUS) for pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Fertility Clinic</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic endometritis</keyword>
  <keyword>invitro fertilization</keyword>
  <keyword>spontaneous abortion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

